DOI: 10.1007/s00259-017-3839-5Pages: 132-150

PET and SPECT imaging of melanoma: the state of the art

1. Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Department of Nuclear Medicine

2. University of Wisconsin–Madison, Department of Radiology

3. University of Wisconsin–Madison, Department of Medical Physics

4. Huazhong University of Science and Technology; Hubei Key Laboratory of Molecular Imaging, Department of Nuclear Medicine, Union Hospital, Tongji Medical College

5. University of Wisconsin Carbone Cancer Center

Correspondence to:
Weibo Cai
Email: wcai@uwhealth.org

Close

Abstract

Melanoma represents the most aggressive form of skin cancer, and its incidence continues to rise worldwide. 18F–FDG PET imaging has transformed diagnostic nuclear medicine and has become an essential component in the management of melanoma, but still has its drawbacks. With the rapid growth in the field of nuclear medicine and molecular imaging, a variety of promising probes that enable early diagnosis and detection of melanoma have been developed. The substantial preclinical success of melanin- and peptide-based probes has recently resulted in the translation of several radiotracers to clinical settings for noninvasive imaging and treatment of melanoma in humans. In this review, we focus on the latest developments in radiolabeled molecular imaging probes for melanoma in preclinical and clinical settings, and discuss the challenges and opportunities for future development.

To access the full text, please Sign in

If you have institutional access, please click here

  • Accepted: Sep 18, 2017
  • Online: Oct 30, 2017

Article Tools

eanm
EJNMMI Ad